Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherClinical Investigations (Human)

Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.

caroline bodet-milin, Alain faivre-chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, delphine Drui, David M Goldenberg, Robert M Sharkey, Jacques Barbet and Francoise Kraeber-Bodere
Journal of Nuclear Medicine February 2021, jnumed.120.252791; DOI: https://doi.org/10.2967/jnumed.120.252791
caroline bodet-milin
1 Universite de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain faivre-chauvet
2 Universite de Nantes, CHU Nantes, CNRS, Inserm, CRCINA,, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Carlier
2 Universite de Nantes, CHU Nantes, CNRS, Inserm, CRCINA,, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Ansquer
2 Universite de Nantes, CHU Nantes, CNRS, Inserm, CRCINA,, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurore Rauscher
3 Pharmacy Unit, ICO Cancer Center,, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Frampas
4 Radiology department, University Hospital,, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
frederique Toulgoat
5 Radiology department, University Hospital, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damien Masson
6 Biology, University Hospital, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mickael Bourgeois
1 Universite de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evelyne Cerato
7 Délégation à la Recherche Clinique et à l'Innovation, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Rohmer
8 Endocrinology Department, University Hospital, Angers, France, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Couturier
9 Nuclear Medicine, University Hospital, Angers, France, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
delphine Drui
10 Endocrinology Department, University Hospital, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M Goldenberg
11 Immunomedics, Inc. ; IBC Pharmaceuticals, Inc., United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert M Sharkey
12 Immunomedics, Inc., United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Barbet
13 GIP Arronax, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francoise Kraeber-Bodere
2 Universite de Nantes, CHU Nantes, CNRS, Inserm, CRCINA,, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction: Pretargeting parameters for use the anti-CEA (carcinoembryonic antigen) bispecific monoclonal antibody TF2 and the 68Ga-labeled IMP288 peptide (68Ga-IMP288) for Immuno-PET have been optimized in a first-in-human study performed in MTC (medullary thyroid carcinoma (MTC) patients (iPET-MTC study). The aim of this post-hoc analysis was to determine the sensitivity of Immuno-PET in relapsing MTC patients, in comparison with conventional imaging and 18F-DOPA PET/CT (DOPA-PET/CT). Methods: Twenty-five studies were analyzed in 22 patients. All patients received Immuno-PET 1-h and 2-h after 68Ga-IMP288 injection pretargeted by TF2, in addition to neck-thoracic-abdominal-pelvic computed tomography (CT), bone and liver magnetic resonance imaging (MRI), and DOPA-PET/CT. Gold standard (GS) was histology and/or confirmation by one other imaging method and/or imaging follow-up. Results: 190 lesions were confirmed by the GS: 89 in lymph nodes, 14 in lungs, 46 in liver, 37 in bone, and 4 in other sites (subcutaneous, heart, brain, and pancreas). 210 abnormal foci were detected by Immuno-PET. Among these, 174 (83%) were confirmed as true-positive by the GS. Immuno-PET showed a higher overall sensitivity (92%) than DOPA-PET/CT (65%). Regarding metastatic sites, Immuno-PET had a higher sensitivity than CT, DOPA-PET/CT or MRI for lymph nodes (98% vs 83% for CT and 70% for DOPA-PET/CT), liver (98% vs 87% for CT, 65% DOPA-PET/CT, and 89% for MRI) and bone (92% vs 64% for DOPA-PET/CT and 86% for MRI), whereas sensitivity was lower for lung metastases (29% vs 100% for CT and 14% for DOPA-PET/CT). Tumor SUVmax at 60 min ranged from 1.2 to 59.0 with intra- and inter-patient variability. Conclusion: This post-hoc study demonstrates that anti-CEA immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than DOPA-PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination.

  • Molecular Imaging
  • Oncology: Endocrine
  • Radioimmunoimaging
  • Immuno-PET
  • bispecific antibody
  • carcinoembryonic antigen
  • medullary thyroid cancer
  • pretargeted radioimmunoimaging
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
caroline bodet-milin, Alain faivre-chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, delphine Drui, David M Goldenberg, Robert M Sharkey, Jacques Barbet, Francoise Kraeber-Bodere
Journal of Nuclear Medicine Feb 2021, jnumed.120.252791; DOI: 10.2967/jnumed.120.252791

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study.
caroline bodet-milin, Alain faivre-chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, delphine Drui, David M Goldenberg, Robert M Sharkey, Jacques Barbet, Francoise Kraeber-Bodere
Journal of Nuclear Medicine Feb 2021, jnumed.120.252791; DOI: 10.2967/jnumed.120.252791
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • 18F-FDG PET/MRI for staging and interim response assessment in pediatric and adolescent Hodgkin lymphoma: a prospective study with 18F-FDG PET/CT as reference standard
  • Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
  • A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
Show more Clinical Investigations (Human)

Clinical(Molecular Imaging: Radioimmunoimaging/Assays/Monoclonal Ab)

  • The navigating and de-risking role of 89Zr-immuno-PET in the development of biopharmaceuticals
Show more Clinical(Molecular Imaging: Radioimmunoimaging/Assays/Monoclonal Ab)

Similar Articles

Keywords

  • molecular imaging
  • Oncology: Endocrine
  • Radioimmunoimaging
  • immuno-PET
  • bispecific antibody
  • carcinoembryonic antigen
  • medullary thyroid cancer
  • pretargeted radioimmunoimaging
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire